FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126792011> ?p ?o ?g. }

• W3126792011 endingPage "1629" @default.
• W3126792011 startingPage "1621" @default.
• W3126792011 abstract "Janus kinase (JAK) inhibitors are used to treat rheumatoid arthritis (RA). We assessed the effects of tofacitinib on bone density and bone markers in association with clinical and laboratory parameters in RA. Tofacitinib stabilized bone density and resulted in a positive balance of bone turnover.Janus kinase (JAK) inhibitors emerged as new therapeutic options in rheumatoid arthritis (RA). We have little information on how it affects areal and volumetric bone mineral density (BMD) and bone turnover markers. The aim of this study was to assess the effects of 1-year tofacitinib therapy on bone metabolism in RA.Thirty RA patients with active disease were treated with either 5 mg bid or 10 mg bid tofacitinib for 12 months. We determined DAS28, CRP, IgM rheumatoid factor (RF), and anti-cyclic citrullinated peptide (CCP) levels, as well as serum levels of sclerostin, osteocalcin (OC), P1NP, DKK-1, OPG, RANKL, and 25-hydroxy-vitamin D3. Areal and volumetric BMD were assessed by DXA and peripheral quantitative CT (QCT), respectively.Twenty-six patients (13 on each arm) completed the study. Tofacitinib was clinically effective by suppressing DAS28, CRP, and HAQ. This was accompanied by the attenuation of further bone loss. Tofacitinib therapy significantly increased OC, OPG, and vitamin D3, while decreased CTX levels (p < 0.05). Age and multiple bone markers (OC, CTX, P1NP, RANKL) inversely correlated with L2-4 and femoral neck BMD by DXA. CRP, DAS28, and RANKL inversely determined volumetric BMD by QCT. Age, CRP, anti-CCP, and DKK-1 influenced the effects of tofacitinib therapy on BMD changes.One-year tofacitinib treatment stabilized BMD in RA patients and resulted in a positive balance of bone turnover as indicated by bone biomarkers. Further studies are needed to evaluate the potential beneficial effects of JAK inhibitors on inflammatory bone loss." @default.
• W3126792011 created "2021-02-15" @default.
• W3126792011 creator A5001954763 @default.
• W3126792011 creator A5009804859 @default.
• W3126792011 creator A5012926852 @default.
• W3126792011 creator A5019904199 @default.
• W3126792011 creator A5020937342 @default.
• W3126792011 creator A5024546145 @default.
• W3126792011 creator A5027176580 @default.
• W3126792011 creator A5028052943 @default.
• W3126792011 creator A5029271774 @default.
• W3126792011 creator A5029915112 @default.
• W3126792011 creator A5029969068 @default.
• W3126792011 creator A5036276929 @default.
• W3126792011 creator A5052648785 @default.
• W3126792011 creator A5054497219 @default.
• W3126792011 creator A5055464565 @default.
• W3126792011 creator A5056967357 @default.
• W3126792011 creator A5061746325 @default.
• W3126792011 creator A5064243798 @default.
• W3126792011 creator A5078842176 @default.
• W3126792011 creator A5084289414 @default.
• W3126792011 creator A5091687940 @default.
• W3126792011 date "2021-02-09" @default.
• W3126792011 modified "2023-10-17" @default.
• W3126792011 title "Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis" @default.
• W3126792011 cites W1671779243 @default.
• W3126792011 cites W1946000754 @default.
• W3126792011 cites W1985968831 @default.
• W3126792011 cites W1993271032 @default.
• W3126792011 cites W1995276823 @default.
• W3126792011 cites W2001010891 @default.
• W3126792011 cites W2006443329 @default.
• W3126792011 cites W2014519035 @default.
• W3126792011 cites W2032362610 @default.
• W3126792011 cites W2035320881 @default.
• W3126792011 cites W2037787276 @default.
• W3126792011 cites W2042817797 @default.
• W3126792011 cites W2060483733 @default.
• W3126792011 cites W2075352837 @default.
• W3126792011 cites W2086103128 @default.
• W3126792011 cites W2093252878 @default.
• W3126792011 cites W2104669609 @default.
• W3126792011 cites W2120393706 @default.
• W3126792011 cites W2126947540 @default.
• W3126792011 cites W2128943170 @default.
• W3126792011 cites W2141621991 @default.
• W3126792011 cites W2156414583 @default.
• W3126792011 cites W2158734690 @default.
• W3126792011 cites W2164327378 @default.
• W3126792011 cites W2254470680 @default.
• W3126792011 cites W2270670296 @default.
• W3126792011 cites W2465475922 @default.
• W3126792011 cites W2529436134 @default.
• W3126792011 cites W2559843514 @default.
• W3126792011 cites W2585530084 @default.
• W3126792011 cites W2593565645 @default.
• W3126792011 cites W2734432177 @default.
• W3126792011 cites W2744427222 @default.
• W3126792011 cites W2912017753 @default.
• W3126792011 cites W2972374662 @default.
• W3126792011 cites W2995463243 @default.
• W3126792011 cites W3001924350 @default.
• W3126792011 cites W3003472716 @default.
• W3126792011 cites W3006157754 @default.
• W3126792011 cites W3039149975 @default.
• W3126792011 cites W3108525427 @default.
• W3126792011 cites W4231972505 @default.
• W3126792011 doi "https://doi.org/10.1007/s00198-021-05871-0" @default.
• W3126792011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8376736" @default.
• W3126792011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33559714" @default.
• W3126792011 hasPublicationYear "2021" @default.
• W3126792011 type Work @default.
• W3126792011 sameAs 3126792011 @default.
• W3126792011 citedByCount "21" @default.
• W3126792011 countsByYear W31267920112021 @default.
• W3126792011 countsByYear W31267920112022 @default.
• W3126792011 countsByYear W31267920112023 @default.
• W3126792011 crossrefType "journal-article" @default.
• W3126792011 hasAuthorship W3126792011A5001954763 @default.
• W3126792011 hasAuthorship W3126792011A5009804859 @default.
• W3126792011 hasAuthorship W3126792011A5012926852 @default.
• W3126792011 hasAuthorship W3126792011A5019904199 @default.
• W3126792011 hasAuthorship W3126792011A5020937342 @default.
• W3126792011 hasAuthorship W3126792011A5024546145 @default.
• W3126792011 hasAuthorship W3126792011A5027176580 @default.
• W3126792011 hasAuthorship W3126792011A5028052943 @default.
• W3126792011 hasAuthorship W3126792011A5029271774 @default.
• W3126792011 hasAuthorship W3126792011A5029915112 @default.
• W3126792011 hasAuthorship W3126792011A5029969068 @default.
• W3126792011 hasAuthorship W3126792011A5036276929 @default.
• W3126792011 hasAuthorship W3126792011A5052648785 @default.
• W3126792011 hasAuthorship W3126792011A5054497219 @default.
• W3126792011 hasAuthorship W3126792011A5055464565 @default.
• W3126792011 hasAuthorship W3126792011A5056967357 @default.
• W3126792011 hasAuthorship W3126792011A5061746325 @default.
• W3126792011 hasAuthorship W3126792011A5064243798 @default.
• W3126792011 hasAuthorship W3126792011A5078842176 @default.

• next